John Johnson
CIK: 0001410781
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Jun 24, 2026AXGN
Axogen, Inc.
Award(A)DirectRestricted Stock Units
4.4K shares- - Jun 19, 2026AXGN
Axogen, Inc.
Exercise(M)Direct14.2K shares- - Jun 4, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct15K shares at avg. $6.09$91K - Jun 4, 2026XERS
Xeris Biopharma Holdings, Inc.
Award(A)Direct24.2K shares- - May 21, 2026VSTM
Verastem, Inc.
Award(A)Direct36K shares- - May 7, 2026AXGN
Axogen, Inc.
Exercise(M)Direct11.1K shares at avg. $7.04$78K - May 7, 2026AXGN
Axogen, Inc.
Sale(S)Direct11.1K shares at avg. $43.26$478K - Dec 19, 2025XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct135.4K shares at avg. $7.22$977K - Dec 9, 2025AXGN
Axogen, Inc.
Exercise(M)Direct8.5K shares at avg. $6.30$54K - Dec 9, 2025AXGN
Axogen, Inc.
Sale(S)Direct13.1K shares at avg. $29.98$394K - Dec 9, 2025AXGN
Axogen, Inc.
Sale(S)Direct8.5K shares at avg. $29.98$256K - Dec 8, 2025AXGN
Axogen, Inc.
Exercise(M)Direct11.9K shares at avg. $6.30$75K - Dec 8, 2025AXGN
Axogen, Inc.
Sale(S)Direct11.9K shares at avg. $31.22$371K - Dec 8, 2025AXGN
Axogen, Inc.
Sale(S)Direct11.8K shares at avg. $31.26$369K - Aug 13, 2025XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct107.5K shares at avg. $7.32$786K - Jun 19, 2025AXGN
Axogen, Inc.
Award(A)DirectRestricted Stock Units
14.2K shares- - Jun 9, 2025AXGN
Axogen, Inc.
Sale(S)Direct4.1K shares at avg. $10.61$43K - Jun 4, 2025XERS
Xeris Biopharma Holdings, Inc.
Award(A)Direct50K shares- - May 22, 2025VSTM
Verastem, Inc.
Award(A)Direct8.3K shares- - Dec 19, 2024APLT
Applied Therapeutics, Inc.
Award(A)Direct500K shares- - Sep 1, 2024AXGN
Axogen, Inc.
Exercise(M)Direct11.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  AXGN Axogen, Inc. | Award(A) Restricted Stock Units | 4,392 | - | - | Direct |
| Jun 19, 2026 | AXGN Axogen, Inc. | Exercise(M) | 14,150 | - | $0 | Direct |
| Jun 4, 2026 |  XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 15,000 | $6.09 | $91,422 | Direct |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | Award(A) | 24,193 | - | $0 | Direct |
| May 21, 2026 |  VSTM Verastem, Inc. | Award(A) | 36,000 | - | $0 | Direct |
| May 7, 2026 | AXGN Axogen, Inc. | Exercise(M) | 11,050 | $7.04 | $77,792 | Direct |
| May 7, 2026 | AXGN Axogen, Inc. | Sale(S) | 11,050 | $43.26 | $477,968 | Direct |
| Dec 19, 2025 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 135,400 | $7.22 | $977,019 | Direct |
| Dec 9, 2025 | AXGN Axogen, Inc. | Exercise(M) | 8,545 | $6.30 | $53,834 | Direct |
| Dec 9, 2025 | AXGN Axogen, Inc. | Sale(S) | 13,141 | $29.98 | $393,993 | Direct |
| Dec 9, 2025 | AXGN Axogen, Inc. | Sale(S) | 8,545 | $29.98 | $256,196 | Direct |
| Dec 8, 2025 | AXGN Axogen, Inc. | Exercise(M) | 11,891 | $6.30 | $74,913 | Direct |
| Dec 8, 2025 | AXGN Axogen, Inc. | Sale(S) | 11,891 | $31.22 | $371,273 | Direct |
| Dec 8, 2025 | AXGN Axogen, Inc. | Sale(S) | 11,802 | $31.26 | $368,931 | Direct |
| Aug 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 107,500 | $7.32 | $786,459 | Direct |
| Jun 19, 2025 | AXGN Axogen, Inc. | Award(A) Restricted Stock Units | 14,150 | - | - | Direct |
| Jun 9, 2025 | AXGN Axogen, Inc. | Sale(S) | 4,073 | $10.61 | $43,215 | Direct |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | Award(A) | 50,000 | - | - | Direct |
| May 22, 2025 | VSTM Verastem, Inc. | Award(A) | 8,333 | - | - | Direct |
| Dec 19, 2024 |  APLT Applied Therapeutics, Inc. | Award(A) | 500,000 | - | $0 | Direct |
| Sep 1, 2024 | AXGN Axogen, Inc. | Exercise(M) | 11,904 | - | $0 | Direct |
1-21 of 21 transactions
About JOHNSON JOHN
JOHNSON JOHN (SEC CIK 0001410781) files insider reports with the SEC as Director of Axogen, Inc. (AXGN), Director of Xeris Biopharma Holdings, Inc. (XERS) and Director of Verastem, Inc. (VSTM). Signal8 also holds filings tied to 1 other company.
Signal8 holds 15 ownership filings by JOHNSON JOHN (1 Form 3, 14 Form 4), filed between Sep 4, 2024 and Jun 26, 2026. Those filings report 21 transactions, from Sep 1, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on JOHNSON JOHN's filings is in CHICAGO, IL.
Recent filings by JOHNSON JOHN
- Jun 24, 2026: Grant or award of AXGN derivative securities (Form 4, code A).
- Jun 19, 2026: Option exercise of AXGN shares (Form 4, code M).
- Jun 4, 2026: Open-market sale of XERS shares (Form 4, code S).
- Jun 4, 2026: Grant or award of XERS shares (Form 4, code A).
- May 21, 2026: Grant or award of VSTM shares (Form 4, code A).
Other insiders filing for Axogen, Inc. (AXGN)
- TYNDALL JOSEPH A., Director
- Began Marc A, EVP & General Counsel
- Wendell Amy McBride, Director
- Weiler Kathy Johnson, Director
- Burke William P. Mr., Director
- Levine Alan M, Director